MRE11 (MRE11A) Related Ataxia- Telangiectasia–Like Disorder 1 (ATLD1)

MRE11 (MRE11A)–related ataxia-telangiectasia–like disorder 1 (ATLD1) is a rare, inherited brain and body condition caused by harmful changes in the MRE11A gene. This gene makes a protein called MRE11, which teams up with two other proteins (RAD50 and NBN/NBS1) to form the MRN complex—a first-responder that detects and repairs broken DNA. When MRE11 does not work properly, brain cells—especially in the cerebellum (the balance and coordination center)—slowly get damaged. People develop progressive ataxia (unsteady movement), eye movement problems (oculomotor apraxia), and slurred speech (dysarthria). Unlike classic ataxia-telangiectasia, ATLD1 usually does not show eye telangiectasias, does not have high alpha-fetoprotein (AFP) levels, and often lacks obvious immune deficiency, but affected cells are very sensitive to X-rays/ionizing radiation. PMC+2Orpha+2

MRE11 ataxia-telangiectasia-like disorder—often shortened to ATLD1—is a rare, inherited brain and DNA-repair disease. It happens when a child gets two faulty copies of the MRE11 gene from their parents. MRE11 is one part of the cell’s “first responder” team for broken DNA called the MRN complex (MRE11-RAD50-NBS1). When MRN is weak, cells cannot correctly sense and fix dangerous DNA double-strand breaks or fully switch on the ATM safety kinase. Over time, this causes slowly progressive cerebellar degeneration, which shows up as unsteady walking (ataxia), slurred speech, and eye-movement problems. Unlike classic ataxia-telangiectasia (A-T), visible telangiectasias are usually absent, immune problems are milder, and the course is typically slower—though cells are very sensitive to medical radiation (X-rays). BioMed Central+3NCBI+3Genetic & Rare Diseases Center+3

---

Other names

• Ataxia-telangiectasia-like disorder 1

• ATLD1

• MRE11-related ATLD / MRE11A-related ATLD

• Atld (historical shorthand in early papers)
  These names all point to the same condition: the A-T–like syndrome caused specifically by MRE11 gene variants. National Organization for Rare Disorders+2Genetic & Rare Diseases Center+2

---

Types

Doctors use “A-T–like disorder” for two genetic subtypes:

1. ATLD1 (MRE11-related) – the topic of this article. It results from biallelic pathogenic variants in MRE11 and gives the classic triad for this group: childhood-onset, slowly progressive ataxia; oculomotor apraxia; and marked cellular radiosensitivity, usually without telangiectasias. NCBI+1

2. ATLD2 (PCNA-related) – a different, much rarer form caused by variants in PCNA, with overlapping but not identical features. Mentioned here only to avoid confusion when reading. PMC+1

MRE11 is a nuclease that “tastes” DNA ends and helps start repair. Working with RAD50 and NBS1, it forms the MRN complex, which brings ATM to the break, starts checkpoint signaling, and prepares the DNA ends for accurate repair. Faulty MRE11 means poor break sensing, weak ATM activation, and error-prone repair, so neurons in the cerebellum gradually fail. This also explains lab hypersensitivity to ionizing radiation. Molecular Biology of the Cell+3Embo Press+3Embo Press+3

---

Causes

ATLD1 is autosomal recessive. The “causes” below are the molecular ways MRE11 faults create disease or make it worse over time.

1. Biallelic loss-of-function MRE11 variants (nonsense/frameshift) reduce or abolish MRE11 protein. ScienceDirect

2. Missense variants that leave the protein present but disable MRE11’s nuclease activity. ScienceDirect

3. Splice-site variants that mis-assemble the MRE11 message, yielding unstable protein. American Academy of Neurology

4. Hypomorphic variants that partially impair function, explaining slower, milder courses. ScienceDirect

5. Failed ATM recruitment/activation because MRN cannot properly signal to ATM. Embo Press

6. Defective DNA end resection, the first cut-back step needed for accurate repair. ScienceDirect

7. Checkpoint failure, so damaged cells keep dividing, accumulating errors. BioMed Central

8. Genomic instability with spontaneous chromosome breaks in patient cells. Genetic & Rare Diseases Center

9. Radiosensitivity—ionizing radiation causes outsized damage in MRN-deficient cells. PMC

10. Protein complex imbalance—faulty MRE11 disrupts MRN cooperation with RAD50/NBS1. Embo Press

11. Reduced DNA-damage signaling to ATR pathways (indirect ATM/ATR crosstalk effects). BioMed Central

12. Telomere maintenance defects reported with MRN dysfunction. PreventionGenetics

13. Neuronal vulnerability—Purkinje cells are especially sensitive to repair failure. (Mechanistic inference grounded in MRN biology.) PMC

14. Oxidative stress sensitivity—ROS creates DNA breaks the cell cannot easily fix. (Mechanistic inference grounded in DSB biology.) PMC

15. Compound heterozygosity—two different pathogenic MRE11 variants produce disease. NCBI

16. Founder variants in some populations leading to clustered cases. (Rare-disease epidemiology note.) Genetic & Rare Diseases Center

17. Protein instability and rapid degradation of variant MRE11. ScienceDirect

18. Disrupted cooperation with CtIP needed for accurate end processing. ScienceDirect

19. Altered ATM substrate phosphorylation after MRN failure. BioMed Central

20. Developmental timing—damage accumulates during growth, so symptoms start in childhood. (Established from clinical series.) NCBI

---

Symptoms

1. Unsteady walking (gait ataxia)—often the first sign in childhood; slowly gets worse. Genetic & Rare Diseases Center

2. Oculomotor apraxia—difficulty starting fast eye movements (saccades); head thrusting. Genetic & Rare Diseases Center

3. Slurred or scanning speech (dysarthria) from cerebellar involvement. MalaCards

4. Poor coordination of arms/legs (limb ataxia)—clumsiness, trouble with fine tasks. MalaCards

5. Frequent falls due to imbalance. MalaCards

6. Abnormal eye movements—impaired smooth pursuit, hypometric saccades. MalaCards

7. Dystonia or chorea in some patients (involuntary movements). MalaCards

8. Mild lower-limb spasticity in some individuals. MalaCards

9. Hyporeflexia (reduced reflexes), sometimes reflecting peripheral involvement. MalaCards

10. Cervical dystonia, newly reported in ATLD1, shows the clinical range. Frontiers

11. Cerebellar atrophy on MRI, correlating with symptoms. MalaCards

12. No visible telangiectasias—helps distinguish from classic A-T. Genetic & Rare Diseases Center

13. Usually milder or absent immune problems compared with classic A-T. Orpha

14. Radiosensitivity as a lab trait—important for medical care decisions. PMC

15. Slower progression than A-T—patients often maintain skills longer. Frontiers

---

Diagnostic tests

A. Physical examination

1. Neurologic exam for ataxia – doctor watches gait, stance, and balance to confirm a cerebellar pattern. Orpha

2. Cranial-nerve and eye-movement exam – looks for oculomotor apraxia and impaired pursuit/saccades. MalaCards

3. Speech assessment – checks for cerebellar dysarthria. MalaCards

4. Reflex testing – reduced reflexes can point to peripheral involvement. MalaCards

5. Skin and eye inspection – absence of telangiectasias supports ATLD1 over classic A-T. Orpha+1

B. Manual bedside coordination tests

6. Finger-to-nose – shows dysmetria (past-pointing) from cerebellar dysfunction. Orpha

7. Heel-to-shin – evaluates leg coordination and truncal stability. Orpha

8. Rapid alternating movements – looks for dysdiadochokinesis, common in ATLD1. MalaCards

9. Tandem (heel-to-toe) gait – sensitive to midline cerebellar problems. Orpha

10. Bedside saccade testing – the clinician asks for quick eye jumps; latency/undershoot suggests oculomotor apraxia. MalaCards

C. Laboratory and pathological tests

11. Targeted or exome/genome genetic testing – confirms biallelic pathogenic MRE11 variants; this is the definitive test. Invitae

12. Cellular radiosensitivity assay – patient cells show hypersensitivity to ionizing radiation in culture. PMC

13. Chromosomal breakage analysis – detects spontaneous chromosomal aberrations. Genetic & Rare Diseases Center

14. MRE11 protein studies (e.g., western blot) – can show reduced/absent protein in some variants (supportive, not required). ScienceDirect

15. Alpha-fetoprotein (AFP) – often normal in ATLD1 (helps distinguish from A-T, where AFP is typically high). NCBI+1

16. Immunoglobulin levels and lymphocyte subsets – usually near-normal or mildly affected (helps exclude classic A-T). Orpha

17. Carrier testing for parents/siblings – once the family’s variants are known, helps with counseling. Invitae

18. Preimplantation/prenatal testing (where appropriate) – uses the known variants to inform future pregnancies. Invitae

D. Electrodiagnostic tests

19. Nerve conduction studies / EMG – may show mild peripheral involvement (e.g., hyporeflexia correlate), and rule out other causes of ataxia. MalaCards

20. Video-oculography – quantifies saccade latency and pursuit deficits in a precise, objective way. Movement Disorders

E. Imaging tests

21. Brain MRI – typically reveals cerebellar atrophy; progression over time supports the diagnosis. MalaCards

22. Spinal MRI (when needed) – rules out other structural causes of imbalance/weakness. (Adjunctive use in ataxia workups.) Orpha

23. Research imaging modalities (e.g., volumetrics) – can measure cerebellar loss more precisely but are not mandatory for care. Movement Disorders

Non-pharmacological treatments (therapies & others)

1. Individualized physical therapy (PT).
   Purpose: Maintain walking, balance, and coordination; prevent falls. Mechanism: Repeated task-specific practice and balance exercises help the brain use alternative pathways to move more safely, even when the cerebellum is weak. PMC

2. Gait and balance training (including cueing).
   Purpose: Reduce falls, improve step length and rhythm. Mechanism: External cues (metronome, visual floor markers) and dynamic balance drills improve movement timing when internal cerebellar timing is unreliable. PMC

3. Occupational therapy (OT).
   Purpose: Make daily tasks like writing, dressing, and eating easier. Mechanism: Adaptive techniques/devices (weighted utensils, button hooks, stabilized work surfaces) reduce tremor impact and improve independence. PMC

4. Speech-language therapy.
   Purpose: Improve speech clarity and safe swallowing. Mechanism: Articulation drills, breath support, pacing strategies, and swallow techniques lower aspiration risk and boost communication. PMC

5. Eye-movement (oculomotor) rehab.
   Purpose: Lessen reading fatigue and head thrusting from oculomotor apraxia. Mechanism: Visual tracking and saccade practice strengthen compensatory eye-head coordination. PMC

6. Strength and flexibility program.
   Purpose: Maintain muscle power and joint range to support mobility. Mechanism: Low-impact resistance and stretching counter deconditioning from reduced activity. PMC

7. Falls-prevention home safety.
   Purpose: Reduce injury risk. Mechanism: Remove tripping hazards, use grab bars, good lighting, and shoes with grip; consider walker/rollator if needed. PMC

8. Nutrition support.
   Purpose: Maintain weight/energy; avoid aspiration. Mechanism: Texture modification, small frequent meals, and dietitian input address dysphagia and calorie needs. PMC

9. Energy conservation & fatigue management.
   Purpose: Extend participation in school/work. Mechanism: Activity pacing, rest scheduling, and assistive tech reduce energy drain from ataxic effort. PMC

10. Psychological support & counseling.
    Purpose: Cope with a chronic progressive disorder. Mechanism: Cognitive-behavioral strategies and family counseling build resilience and reduce anxiety/depression burden. PMC

11. Educational accommodations.
    Purpose: Keep learning on track. Mechanism: Extra time, note-taking aids, speech-to-text, and physical access plans support school performance. PMC

12. Orthotics & mobility aids.
    Purpose: Safer walking and hand function. Mechanism: Ankle-foot orthoses, weighted wrist cuffs, or forearm supports damp tremor and improve stance. PMC

13. Constraint-induced and task-oriented training.
    Purpose: Improve use of a weaker side/skill. Mechanism: Intensive, repetitive practice drives neuroplastic changes to refine motor control. PMC

14. Spasticity/dystonia positioning & seating.
    Purpose: Comfort, skin protection, safe feeding. Mechanism: Custom seating and positioning reduce abnormal postures and pressure points. PMC

15. Swallow therapy & aspiration precautions.
    Purpose: Prevent pneumonia and weight loss. Mechanism: Postural strategies (chin tuck), safe textures, and pacing lower aspiration risk. PMC

16. Sleep hygiene optimization.
    Purpose: Improve daytime function and balance. Mechanism: Regular schedules and minimizing nocturnal disruptions support cerebellar learning. PMC

17. Vaccination & infection prevention (general).
    Purpose: Reduce illness that can worsen weakness/ataxia. Mechanism: Age-appropriate vaccines and hand hygiene; avoid live vaccines only if specific immune defects are documented by clinicians. Immune Deficiency Foundation

18. Genetic counseling.
    Purpose: Family planning and carrier testing. Mechanism: Explains autosomal recessive inheritance and recurrence risks. Orpha

19. Radiation-minimization protocols.
    Purpose: Protect radiosensitive tissues. Mechanism: Prefer MRI/ultrasound; if imaging is needed, use the lowest feasible dose and alternatives to CT/X-ray. BioMed Central

20. Multidisciplinary follow-up.
    Purpose: Coordinate care over time. Mechanism: Regular reviews by neurology, rehab, nutrition, ophthalmology, and primary care. PMC

---

Drug treatments

Important safety note: There is no proven disease-modifying drug for ATLD1. The medicines below are standard treatments for symptoms (dystonia, spasticity, tremor, anxiety, etc.) used in other neurologic disorders and sometimes reported in ATLD/AT care. Exact dosing must be individualized by a clinician based on age, weight, and comorbidities; do not start/adjust any medicine without your doctor. PMC

1. Botulinum toxin (for focal dystonia/blepharospasm).
   Class: Neurotoxin (chemodenervation). Timing: Injections every ~3 months. Purpose: Relax overactive muscles causing abnormal postures or eyelid spasm. Mechanism: Blocks acetylcholine release at the neuromuscular junction. Side effects: Local weakness, dry eye/mouth; rare spread effects. PMC

2. Levodopa (trial for dystonia).
   Class: Dopaminergic. Timing: Divided doses. Purpose: Some dystonias improve with dopamine replacement. Mechanism: Increases brain dopamine. Side effects: Nausea, dizziness, dyskinesia in long use. PMC

3. Baclofen.
   Class: GABA-B agonist antispasmodic. Purpose: Reduce spasticity or generalized dystonia tone. Mechanism: Enhances inhibitory signals in spinal cord. Side effects: Sleepiness, weakness; taper to avoid withdrawal. PMC

4. Clonazepam.
   Class: Benzodiazepine. Purpose: Calm myoclonus/tremor or dystonia. Mechanism: GABA-A enhancement. Side effects: Sedation, falls, dependence with long use. PMC

5. Trihexyphenidyl or Biperiden.
   Class: Anticholinergics. Purpose: Reduce dystonia severity. Mechanism: Lowers acetylcholine activity in basal ganglia. Side effects: Dry mouth, blurred vision, confusion (especially in older adults). PMC

6. Propranolol.
   Class: Beta-blocker. Purpose: Dampen action tremor that sometimes coexists with ataxia. Mechanism: Blocks beta-adrenergic effects on muscle tremor. Side effects: Bradycardia, fatigue; avoid in asthma. PMC

7. Primidone.
   Class: Anticonvulsant (barbiturate derivative). Purpose: Alternative for action tremor. Mechanism: Increases GABAergic inhibition. Side effects: Sedation, nausea, imbalance at initiation. PMC

8. Gabapentin/Pregabalin.
   Class: Alpha-2-delta ligands. Purpose: Neuropathic pain, tremor modulation in some patients. Mechanism: Reduces excitatory neurotransmitter release. Side effects: Drowsiness, edema. PMC

9. SSRIs/SNRIs (e.g., sertraline, duloxetine).
   Class: Antidepressants. Purpose: Treat depression/anxiety that can accompany chronic neurologic disease. Mechanism: Serotonin ± norepinephrine reuptake inhibition. Side effects: GI upset, sleep changes, sexual dysfunction. PMC

10. Melatonin.
    Class: Chronobiotic. Purpose: Sleep regulation to improve daytime motor performance and rehab engagement. Mechanism: Resets circadian rhythms. Side effects: Morning grogginess in some. PMC

11. Acetazolamide (selected cases of episodic ataxia-like spells).
    Class: Carbonic anhydrase inhibitor. Purpose: Reduce intermittent ataxia episodes (empiric, case-based). Mechanism: Changes neuronal excitability via pH/ion effects. Side effects: Paresthesia, kidney stone risk. PMC

12. Amantadine.
    Class: Dopaminergic/antiglutamatergic. Purpose: Modest help for fatigue or bradykinesia-like slowness. Mechanism: Enhances dopamine release; NMDA modulation. Side effects: Livedo reticularis, insomnia. PMC

13. Tizanidine.
    Class: Alpha-2 agonist. Purpose: Muscle tone control. Mechanism: Reduces excitatory neurotransmission at spinal interneurons. Side effects: Drowsiness, dry mouth, low blood pressure. PMC

14. Topical/short-course NSAIDs or acetaminophen.
    Class: Analgesics. Purpose: Musculoskeletal pain from abnormal tone/posture. Mechanism: Anti-inflammatory or central analgesia. Side effects: GI/renal (NSAIDs), hepatic (acetaminophen at high doses). PMC

15. Antisialogogues for drooling (glycopyrrolate) or botulinum toxin to salivary glands.
    Purpose: Improve comfort/social participation if oromotor control is poor. Mechanism: Reduce saliva production or gland output. Side effects: Dry mouth, constipation; procedure-related discomfort. PMC

16. Antiemetics (ondansetron) during acute illness if dysautonomia-like nausea).
    Purpose: Maintain hydration and oral intake. Mechanism: 5-HT3 blockade. Side effects: Constipation, headache. PMC

17. Laxatives/stool softeners as needed.
    Purpose: Manage constipation from reduced mobility or anticholinergic meds. Mechanism: Osmotic or stimulant bowel action. Side effects: Bloating, cramps. PMC

18. Proton-pump inhibitor (PPI) when reflux worsens dysphagia-related aspiration risk.
    Purpose: Protect esophagus and lungs. Mechanism: Lowers stomach acid. Side effects: Long-term: low Mg, B12 in some. PMC

19. Short-course antibiotics per guidelines for bacterial infections.
    Purpose: Treat intercurrent infections promptly (illness can worsen ataxia). Mechanism: Pathogen-specific. Side effects: Drug-specific. (Chosen by clinician.) Immune Deficiency Foundation

20. Immunoglobulin replacement (only if a clinician documents a specific antibody deficiency).
    Purpose: Prevent recurrent infections in the small subset with proven humoral defects. Mechanism: Provides functional antibodies. Side effects: Headache, infusion reactions. (Note: Most ATLD1 patients do not have clear immunodeficiency.) SAGE Journals

---

Dietary molecular supplements

Evidence caveat: No supplement is proven to change ATLD1 progression. These are supportive options sometimes used for neurologic wellness; discuss with your clinician to avoid drug–supplement interactions.

1. Vitamin D (with calcium if needed).
   Function: Bone health and fall-injury prevention. Mechanism: Supports calcium absorption and muscle function; corrects deficiency common in reduced mobility. PMC

2. Omega-3 fatty acids.
   Function: General anti-inflammatory support; may aid mood. Mechanism: Modulate membrane lipids and inflammatory signaling. PMC

3. Coenzyme Q10.
   Function: Cellular energy support; sometimes used in ataxia clinics. Mechanism: Electron transport chain cofactor; antioxidant role. PMC

4. B-complex with B12.
   Function: Nerve health; correct hidden deficiencies affecting neuropathy or fatigue. Mechanism: Cofactors for myelin and energy metabolism. PMC

5. Magnesium (if low).
   Function: Muscle function and cramp control. Mechanism: Cofactor in neuromuscular signaling. PMC

6. Creatine.
   Function: May support short-burst muscle energy in rehabilitation. Mechanism: Replenishes phosphocreatine stores in muscle. PMC

7. N-acetylcysteine (NAC).
   Function: Antioxidant support. Mechanism: Glutathione precursor; reduces oxidative stress. PMC

8. L-carnitine (if documented deficiency/fatigue).
   Function: Fatty-acid transport into mitochondria. Mechanism: Supports energy production. PMC

9. Fiber supplement (psyllium/inulin).
   Function: Constipation prevention when mobility is reduced. Mechanism: Increases stool bulk and motility. PMC

10. Probiotics (selected cases).
    Function: GI comfort; may reduce antibiotic-associated diarrhea. Mechanism: Microbiome modulation. PMC

---

Immunity-booster / regenerative / stem-cell drugs

• There are no approved “immunity-booster,” regenerative, or stem-cell drugs for ATLD1. Transplant-type treatments (e.g., hematopoietic stem cell transplantation) are not established for ATLD1 and could be harmful in a radiosensitive disorder. Any regenerative or cell-based therapy should be considered experimental only inside a properly approved clinical trial. Avoid ionizing radiation–based conditioning regimens where possible. BioMed Central

What clinicians sometimes optimize instead (supportive “6-pack”):

1. Vaccinations per national schedule (non-live if immune defect is proven). Function: Prevent infections that derail rehab. Mechanism: Trains adaptive immunity. Immune Deficiency Foundation

2. Prompt antimicrobial treatment of bacterial infections. Function: Avoid prolonged deconditioning. Mechanism: Pathogen clearance. Immune Deficiency Foundation

3. Nutritional repletion (protein, vitamin D, iron/B12 if low). Function: Tissue repair co-factors. Mechanism: Supplies substrates for neuronal and muscular health. PMC

4. Targeted physical rehabilitation (neuroplasticity). Function: Functional regeneration by training remaining circuits. Mechanism: Activity-dependent plasticity. PMC

5. Sleep optimization (melatonin if needed). Function: Memory/learning of motor skills. Mechanism: Consolidation during sleep. PMC

6. Psychological resilience programs. Function: Better engagement with long-term therapy. Mechanism: Stress-response modulation. PMC

---

Surgeries (when and why)

There are no ATLD1-specific curative surgeries. Operations are only for complications, and teams must plan radiation-minimizing pathways (e.g., avoid CT when MRI suffices). Examples:

1. Feeding-tube (PEG) placement for severe, unsafe swallowing with weight loss—supports nutrition and lowers aspiration risk. PMC

2. Orthopedic procedures (e.g., tendon lengthening/spinal support) for fixed contractures or scoliosis that block mobility and breathing. PMC

3. Deep brain stimulation (DBS) for severe, medication-refractory dystonia—case-by-case only; evidence in ATLD1 is limited; discuss risks carefully. PMC

4. Salivary-gland botulinum injections (minimally invasive) for severe drooling—reduces aspiration and skin breakdown. PMC

5. Strabismus or eyelid surgeries in select cases to improve function or comfort; ophthalmology-led decisions. PMC

---

Preventions (practical)

• Avoid or minimize ionizing radiation (prefer MRI/US; shield carefully if unavoidable). BioMed Central

• Vaccinate appropriately and treat infections promptly. Immune Deficiency Foundation

• Home fall-prevention (lighting, remove rugs, grab bars). PMC

• Regular PT/OT/speech to slow disability. PMC

• Bone health (vitamin D, weight-bearing as able). PMC

• Swallow safety (texture, posture). PMC

• Medication review to avoid sedatives that worsen balance. PMC

• Adequate sleep and daytime activity pacing. PMC

• Genetic counseling for family planning. Orpha

• Regular multidisciplinary follow-up to catch problems early. PMC

---

When to see a doctor (red flags)

• New or rapidly worsening walking problems, frequent falls, or new head injuries. PMC

• Choking, coughing with meals, or weight loss (possible unsafe swallowing). PMC

• Uncontrolled dystonia/spasms or pain that limits care or sleep. PMC

• Fever, productive cough, or repeated infections. Immune Deficiency Foundation

• Severe fatigue, mood change, or sleep disruption impacting function. PMC

---

What to eat and what to avoid (simple)

Eat more of:
Soft, high-protein foods (eggs, yogurt, lentils, fish), fruits/vegetables, whole-grain carbs, healthy fats (olive oil, nuts), and adequate fluids. Modify textures to match swallow safety. PMC

Limit/avoid:
Alcohol (worsens balance), ultra-processed foods high in sugar/salt (fatigue/blood pressure), and choking-risk textures (dry meats, mixed thin-liquid/solid soups) unless a speech therapist approves. PMC

---

FAQs

1. Is there a cure?
   No. ATLD1 treatment is supportive; research is ongoing into MRN/ATM-ATR biology. Nature

2. Is ATLD1 the same as A-T?
   No—similar mechanisms and symptoms, but different genes and lab features (ATLD1 often normal AFP; A-T high AFP). PMC+1

3. How is it inherited?
   Autosomal recessive—a child inherits one nonworking MRE11A from each parent. Orpha

4. What tests confirm it?
   Genetic testing (MRE11A). MRI may show cerebellar atrophy; cells show radiosensitivity. PMC

5. Are patients immune-deficient?
   Usually not in ATLD1 (unlike A-T), but doctors still check immune function. PMC

6. Can X-rays be dangerous?
   Cells are radiosensitive; teams try to avoid/limit ionizing radiation. BioMed Central

7. Any cancer risk?
   Defects in DNA repair can raise risk in some MRN-related contexts, but data in ATLD1 are limited; clinicians remain vigilant. BioMed Central

8. Do rehab therapies help?
   Yes—PT/OT/speech are core treatments to keep function and safety. PMC

9. Can dystonia be treated?
   Yes—botulinum toxin and medicines like levodopa, baclofen, clonazepam, anticholinergics may help symptoms. PMC

10. What about stem-cell therapy?
    Not established for ATLD1; experimental only within trials. BioMed Central

11. Are supplements useful?
    They may support general health; none are proven to change disease course. PMC

12. Why is AFP normal in ATLD1?
    Because AFP elevation is typical of A-T, not ATLD1; normal AFP can point toward ATLD. PMC

13. What everyday steps help most?
    Fall-proof the home, keep up rehab, sleep well, and keep vaccinations current. PMC+1

14. Can children go to regular school?
    Often yes with accommodations (extra time, assistive tech). PMC

15. Where to learn more?
    Orphanet disease summary and peer-reviewed reviews on ATLD/AT. Orpha

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 24, 2025.